Active Biotech's President & CEO Sven Andréasson and
CFO Hans Kolam will present and comment on the Year End report January-December, 2004.
To listen and to view the presentation: please visit www.activebiotech.com.
To listen and to view the presentation: please visit www.activebiotech.com.
To participate in the teleconference, please call +44 (0) 20 7162 0181 (UK).
To listen to the conference and/or to view the presentation afterwards, please call +44 (0) 20 7031 4064 (UK), access code 642871 or visit www.activebiotech.com.
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases, as well as a novel concept for use in cancer immunotherapy.
Active Biotech AB
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50